(1) The committee serves as a consultative and advisory body to the Legislature regarding:

1. (a) the movement of a controlled substance from one schedule or list to another;
2. (b) the removal of a controlled substance from any schedule or list; and
3. (c) the designation of a substance as a controlled substance and the placement of the substance in a designated schedule or list.

(2) On or before September 30 of each year, the committee shall submit to the Health and Human Services Interim Committee a written report:

1. (a) describing any substances recommended by the committee for scheduling, rescheduling, listing, or deletion from the schedules or list by the Legislature; and
2. (b) stating the reasons for the recommendation.

(3) In advising the Legislature regarding the need to add, delete, relist, or reschedule a substance, the committee shall consider:

1. (a) the actual or probable abuse of the substance, including:

   1. (i) the history and current pattern of abuse both in Utah and in other states;
   2. (ii) the scope, duration, and significance of abuse;
   3. (iii) the degree of actual or probable detriment to public health which may result from abuse of the substance; and
   4. (iv) the probable physical and social impact of widespread abuse of the substance;

2. (b) the biomedical hazard of the substance, including:

   1. (i) its pharmacology, including the effects and modifiers of the effects of the substance;
   2. (ii) its toxicology, acute and chronic toxicity, interaction with other substances, whether controlled or not, and the degree to which it may cause psychological or physiological dependence; and
   3. (iii) the risk to public health and the particular susceptibility of segments of the population;
3. (c) whether the substance is an immediate precursor, as defined in Section 58-37-2, of a substance that is currently a controlled substance;
4. (d) the current state of scientific knowledge regarding the substance, including whether there is any acceptable means to safely use the substance under medical supervision;

5. (e) the relationship between the use of the substance and criminal activity, including whether:

   1. (i) persons engaged in illicit trafficking of the substance are also engaged in other criminal activity;
   2. (ii) the nature and relative profitability of manufacturing or delivering the substance encourages illicit trafficking in the substance;
   3. (iii) the commission of other crimes is one of the recognized effects of abuse of the substance; and
   4. (iv) addiction to the substance relates to the commission of crimes to facilitate the continued use of the substance;
6. (f) whether the substance has been scheduled by other states; and
7. (g) whether the substance has any accepted medical use in treatment in the United States.